NCT01999894 - Open-label Study of Safety and Tolerability of Memantine in Children With Autism | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

AutismPediatric Autism

Interventions

DRUG

Memantine HCl

Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.

Trial Locations (19)

10030

Forest Investigative Site 017, Manhasset

32250

Forest Investigative Site 024, Jacksonville Beach

33701

Forest Investigative Site 007, St. Petersburg

43210

Forest Investigative Site 001, Columbus

44106

Forest Investigative Site 013, Cleveland

Forest Investigative Site 015, Cleveland

46202

Forest Investigative Site 010, Indianapolis

60169

Forest Investigative Site 014, Hoffman Estates

60563

Forest Investigative Site 023, Naperville

73116

Forest Investigative Site 019, Oklahoma City

85006

Forest Investigative Site 005, Phoenix

92701

Forest Investigative Site 026, Santa Ana

92705

Forest Investigative Site 020, Santa Ana

94143

Forest Investigative Site 021, San Francisco

94305

Forest Investigative Site 002, Stanford

95817

Forest Investigative Site 003, Sacramento

02138

Forest Investigative Site 025, Cambridge

08755

Forest Investigative Site 011, Toms River

08043

Forest Investigative Site 006, Voorhees Township